NYSE: GSK
Gsk PLC Stock

$38.97+0.91 (+2.39%)
Updated Apr 29, 2025
Why Price Moved
GSK Price
$38.97
Fair Value Price
N/A
Market Cap
$79.51B
52 Week Low
$31.72
52 Week High
$45.93
P/E
24.36x
P/B
4.59x
P/S
1.75x
PEG
0.52x
Dividend Yield
3.98%
Revenue
$39.72B
Earnings
$3.22B
Gross Margin
71.2%
Operating Margin
12.02%
Profit Margin
8.2%
Debt to Equity
3.39
Operating Cash Flow
$8B
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GSK Overview

GSK plc is a pharmaceutical company operating in several therapeutic classes, including respiratory, oncology, and antiviral. It also offers vaccines and consumer healthcare products. Known as GlaxoSmithKline plc until 2022, the company was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. It is headquartered in London, UK.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine GSK's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: General Drug Manufacturer

Industry Rating
A
GSK
Ranked
#7 of 18

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$113.45A
$71.71A
$155.91A
View Top General Drug Manufacturer Stocks

Be the first to know about important GSK news, forecast changes, insider trades & much more!

GSK News

Overview

Due Diligence Score

Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GSK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GSK ($38.97) is trading above its intrinsic value of $35.45, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GSK is good value based on its earnings relative to its share price (24.36x), compared to the US market average (29.19x)
P/E vs Market Valuation
GSK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more GSK due diligence checks available for Premium users.

Valuation

GSK price to earnings (PE)

For valuing profitable companies with steady earnings

Company
24.36x
Industry
54.14x
Market
29.19x
GSK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GSK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

GSK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.59x
Industry
6.28x
GSK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GSK price to earnings growth (PEG)

For valuing profitable companies with growth potential

GSK is good value based... subscribe to Premium to read more.
PEG Value Valuation

GSK's financial health

Profit margin

Revenue
$10.1B
Net Income
$517.5M
Profit Margin
5.1%
GSK's Earnings (EBIT) of $4.77B... subscribe to Premium to read more.
Interest Coverage Financials
GSK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$74.3B
Liabilities
$58.0B
Debt to equity
3.39
GSK's short-term liabilities ($27.46B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GSK's long-term liabilities ($31.24B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GSK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GSK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.9B
Investing
-$1.4B
Financing
-$1.1B
GSK's operating cash flow ($8.30B)... subscribe to Premium to read more.
Debt Coverage Financials

GSK vs General Drug Manufacturer Stocks

TickerZen RatingMarket Cap1d %P/EP/B
GSKB$79.51B+2.39%24.36x4.59x
BMYA$100.17B+1.57%18.37x5.76x
GILDA$129.78B-2.00%274.24x6.71x
PFEB$134.83B+3.21%16.75x1.53x
SNYC$135.71B+1.82%23.23x1.68x

Gsk Stock FAQ

What is Gsk's quote symbol?

(NYSE: GSK) Gsk trades on the NYSE under the ticker symbol GSK. Gsk stock quotes can also be displayed as NYSE: GSK.

If you're new to stock investing, here's how to buy Gsk stock.

What is the 52 week high and low for Gsk (NYSE: GSK)?

(NYSE: GSK) Gsk's 52-week high was $45.93, and its 52-week low was $31.72. It is currently -15.14% from its 52-week high and 22.88% from its 52-week low.

How much is Gsk stock worth today?

(NYSE: GSK) Gsk currently has 4,080,818,273 outstanding shares. With Gsk stock trading at $38.97 per share, the total value of Gsk stock (market capitalization) is $79.51B.

Gsk stock was originally listed at a price of $59.84 in Dec 31, 1997. If you had invested in Gsk stock at $59.84, your return over the last 27 years would have been -34.88%, for an annualized return of -1.58% (not including any dividends or dividend reinvestments).

How much is Gsk's stock price per share?

(NYSE: GSK) Gsk stock price per share is $38.97 today (as of Apr 29, 2025).

What is Gsk's Market Cap?

(NYSE: GSK) Gsk's market cap is $79.51B, as of Apr 30, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gsk's market cap is calculated by multiplying GSK's current stock price of $38.97 by GSK's total outstanding shares of 4,080,818,273.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.